I’m very happy to have joined a very exciting start-up that hopes to revolutionize surgical care for men with intermediate grade prostate cancer. The standard of care today for these men is a radical prostatectomy which has very severe side-effects including urinary incontinence and erectile dysfunction. Our new technology is a “focal therapy” that leverages a “cooled” laser to deliver a very precise ablation to targeted malignant tissue.
This solution has been available for 3+ years in Australia and just recently in the UK via a special access / exceptional use, authorized prescriber scheme, but we expect Regulatory Approval in these 2 countries in Q4-2026, and then we’ll be focusing our attention on winning Market Access in the USA.
In other news, we have just launched our Series A capital raise by closing an investment with our first, institutional, professional venture investment fund – Bioshores Ventures from Sydney who focus entirely on promising medical device companies. If you’re in the Sydney Northern suburbs, please drop by to say hello.
Eric Davis
Chief Innovation & Commercialization Officer
Medlogical Innovations
Contact Eric at his LinkedIn profile or [email protected].
Back to the Alumni News list.